U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07804030) titled 'AI-Assisted Patient Support in mHSPC' on Sept. 01.
Brief Summary: The purpose of this multicenter, open-label, randomized controlled trial is to evaluate whether patient-centered support delivered through a large language model (LLM)-based artificial intelligence (AI) agent reduces anxiety in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Participants access the AI agent through a WeChat Mini Program-based platform. The study will also assess the effects of this intervention on illness perception, sleep quality, and patient satisfaction. Participants will be randomly assigned in a 1:1 ratio to ei...